Strategic Advisors LLC Sells 7,482 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Posted by Brian Himes on Aug 31st, 2026

Strategic Advisors LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 90.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 812 shares of the pharmaceutical company’s stock after selling 7,482 shares during the period. Strategic Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $403,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of VRTX. Summit Global Investments bought a new position in shares of Vertex Pharmaceuticals during the second quarter worth $3,568,000. Allworth Financial LP boosted its holdings in shares of Vertex Pharmaceuticals by 414.1% during the 4th quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock valued at $6,363,000 after purchasing an additional 11,306 shares during the last quarter. Calamos Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals by 77.1% in the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after purchasing an additional 33,917 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its position in shares of Vertex Pharmaceuticals by 11.9% in the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock worth $15,625,000 after buying an additional 3,710 shares in the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new position in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $13,823,000. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on VRTX. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Sanford C. Bernstein raised shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. Cantor Fitzgerald increased their price objective on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Truist Financial lifted their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $563.50.

View Our Latest Research Report on Vertex Pharmaceuticals

Insider Activity at Vertex Pharmaceuticals

In related news, CMO Carmen Bozic sold 596 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $482.50, for a total value of $287,570.00. Following the completion of the sale, the chief marketing officer directly owned 15,337 shares in the company, valued at $7,400,102.50. This trade represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the transaction, the executive vice president directly owned 11,001 shares of the company’s stock, valued at $5,709,519. The trade was a 12.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 10,464 shares of company stock worth $4,959,397. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $541.69 on Monday. Vertex Pharmaceuticals Incorporated has a 1 year low of $374.17 and a 1 year high of $555.69. The stock’s 50 day simple moving average is $502.08 and its two-hundred day simple moving average is $468.65. The company has a market cap of $137.48 billion, a PE ratio of 31.53, a price-to-earnings-growth ratio of 2.35 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The company had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the previous year, the business earned $4.52 earnings per share. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.